Drug Profile
Research programme: proteolysis targeting chimeric molecules - GlaxoSmithKline/Yale
Alternative Names: protein degrading therapeutics - GlaxoSmithKline/YaleLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Yale University
- Developer GSK; Yale University
- Class
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 01 May 2012 Early research in Undefined indication in United Kingdom (unspecified route)